Boehringer Ingelheim and Berg to Collaborate on Finding Biomarkers for Inflammatory Conditions
Boehringer Ingelheim will use the partnership to reveal novel insights into the complexities of various inflammatory diseases, which opens the potential for a clearer understanding of potential candidate biomarkers.
Berg, a Framingham, MA-based clinical-stage biotechnology company focused on the use of artificial intelligence, and Boehringer Ingelheim announced on May 6, 2020 that they are entering into a collaboration to find candidate biomarkers for inflammatory conditions.
According to a Berg press release, Boehringer Ingelheim will use the partnership to reveal novel insights into the complexities of various inflammatory diseases, which opens the potential for a clearer understanding of potential candidate biomarkers.
“We’re excited to partner with Boehringer Ingelheim, which will combine Boehringer Ingelheim’s translational medicine and biomarker expertise with Berg’s next generation AI-driven, patient-biology capability,” said Dr. Niven R. Narain, Berg co-founder, president, and CEO, in the press release. “Our intent is for Berg’s Interrogative Biology platform to enable the discovery of biomarkers that will revolutionize how to diagnose and treat patients with inflammatory diseases.
Source: Berg
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
